Board of Directors

Joseph B. Martin, MD, PhD (Chair)

Joseph B. Martin, M.D., Ph.D. was appointed the Edward R. and Anne G. Lefler Professor of Neurobiology at Harvard Medical School in July 2007.

Prior to this appointment, Dr. Martin served for ten years as Dean of the Faculty of Medicine at Harvard University. At Harvard, he helped establish, in 1999, the Dana-Farber/Harvard Cancer Center, and in 2001, with the support of an anonymous donor, Dr. Martin formed the Harvard center for Neurodegeneration and Repair, dedicated to understanding the prevention, causes, and treatment of neurodegenerative diseases. In 2003, Dr. Martin dedicated Harvard Medical School's New Research Building, which is designed to cultivate scientific collaboration between the basic and clinical sciences.

From 1989-1993 Dr. Martin served for four years as Dean of the School of Medicine at UCSF. During his tenure as Dean, he established the W.M. Keck Foundation Center for Integrative Neurosciences, the Gladstone Institute for Virology and Immunology, and began planning for a Comprehensive Cancer Center. In 1993, he was appointed Chancellor of UCSF.

Dr. Martin served on the Faculty of Medicine at McGill University in Montreal from 1970-1978. Following his tenure at McGill, he was chief of the Neurology Service at Massachusetts General Hospital and Julieanne Dorn Professor of Neurology at HMS from 1978-1989. At the Massachusetts General Hospital, he led the development in neurogenetics of neurodegenerative disorders, leading to the discovery of the gene for HD.

Dr. Martin received his premedical and medical education at the University of Alberta, Edmonton, earning the M.D. degree in 1962. He completed a residency in neurology in 1966 and fellowship in neuropathology in 1967 at Case Western Reserve University in Cleveland, Ohio, and received his Ph.D. in anatomy from the University of Rochester in 1971.

Henri Termeer (Chair Emeritus)

Henri A. Termeer was appointed president of Genzyme Corporation in 1983, two years after the company's founding. He became its chief executive officer in 1985 and chairman in 1988. Under his leadership, Genzyme has grown from a modest entrepreneurial venture to one of the world's leading biotechnology companies, and in 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

Mr. Termeer is recognized as a pioneer in developing and delivering treatments to patients with rare genetic diseases around the world. He is a trustee for the Boston Museum of Science, a member of the Massachusetts Institute of Technology Corporation and a member of the board of directors of Project HOPE, an international nonprofit health education and humanitarian assistance organization.

Widely acknowledged for his contributions to the biotechnology industry and health care field, Mr. Termeer serves on the board of directors of both the Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America. He is a director of Massachusetts General Hospital and is a member of the board of fellows of Harvard Medical School. In addition, Mr. Termeer is deputy chairman of the Federal Reserve Bank of Boston's board of directors and a member of the board of directors of Abiomed Inc. He was also instrumental in founding the New England Healthcare Institute.

A Native of the Netherlands, Mr. Termeer studied economics at the Economische Hogeschool (Erasmus University, The Netherlands) and earned an M.B.A from the Darden School at the University of Virginia.

Burt Adelman, MD (Vice Chair)

Burt A. Adelman, M.D. was previously Executive Vice President, Research and Development at Biogen, a position he attained in October 2001. Prior to that time, Dr. Adelman was Vice President of Medical Research. He began his career with Biogen in 1991, joining the company as Director of Medical Research, and has held positions of increasing responsibility including Vice President, Regulatory Affairs, and Vice President, Development Operations. In that role he oversaw the Preclinical Development, Medical Operations and Regulatory Affairs groups. Since 1992, Dr. Adelman has served as a lecturer at Harvard Medical School. He is a member of the Board of Directors for the New England Healthcare Institute (NEHI).

Harris A. Berman, MD (Vice Chair)

Harris A. Berman, MD is vice dean at the Tufts University School of Medicine. Prior to his current role, he was a pioneer in the development of managed care in New England, and for 17 years, the CEO of the Tufts Health Plan. During that tenure, Tufts Health Plan grew from 60,000 to over a million members.

Before joining Tufts Health Plan, Dr. Berman co-founded the Matthew Thornton Health Plan in Nashua, NH, one of the first HMOs in New England. He served initially as the HMO’s Medical Director beginning in 1971, then as its Executive Director. He has served as chairman of the Massachusetts Association of HMOs, chairman of Affiliated Health Information Networks of New England, a director of the American Association of Health Plans, and is still Chairman of the Board of the Bank of America Celebrity Series and a member of the Board of Directors of the New England Medical Center, AvMed Health Plan of Florida, and Hebrew Senior Life. Dr. Berman recently became Chairman of the Board of the Massachusetts Health Quality Partners. In addition, Dr. Berman has international experience as a Peace Corps Physician and a consultant to the U.S. Agency for International Development in several international projects.

A graduate of Harvard College and Columbia University College of Physicians and Surgeons, Dr. Berman served as a resident on the Harvard Medical Service of Boston City Hospital and at Tufts-New England Medical Center, and an Infectious Disease fellowship at Tufts-New England Medical Center. He is a fellow of the American College of Physicians.

Nick Littlefield (Vice Chair)

Nick Littlefield, Partner and Co-Chair, Government Strategies Group, at Foley Hoag LLP, concentrates his practice in the areas of biotechnology, biomedical research and health care technology. He specializes in regulatory, administrative and legislative issues for large and small companies, non profit organizations and trade associations. Nick and his colleagues in the Foley Hoag Life Sciences Group work from offices in Boston and Washington. For nine years until 1998, Nick served as Staff Director and Chief Counsel for Massachusetts Senator Edward M.Kennedy on the United States Senate Health, Education, Labor and Pensions Committee, where he worked extensively on biomedical research, health policy, and life sciences regulatory and legislative initiatives. Previously, he taught at Harvard Law School and was an Assistant United States Attorney in the Southern District of New York. He is a graduate of Harvard College and the University of Pennsylvania Law School.

Joshua Boger, PhD (Clerk)

Dr. Joshua Boger is the founder, President and Chief Executive Officer of Vertex Pharmaceuticals Incorporated. He has been the Company’s CEO since 1992, and also served in the additional role of Chairman of the Board from 1997 until 2006. Dr. Boger served as Vertex’s Chief Scientific Officer from 1989 until 1992 and has been a Director since Vertex’s inception.

Dr. Boger holds a B.A. in chemistry and in philosophy from Wesleyan University and M.S. and Ph.D. degrees in chemistry from Harvard University. His postdoctoral research in molecular recognition was performed in the laboratories of the Nobel-prize winning chemist, Jean-Marie Lehn in Strasbourg, France.

Prior to founding Vertex in 1989, Dr. Boger held the position of Senior Director of Basic Chemistry at Merck Sharp & Dohme Research Laboratories in Rahway, New Jersey, where he headed both the Department of Medicinal Chemistry of Immunology & Inflammation and the Department of Biophysical Chemistry.

John Littlechild (Treasurer)

John Littlechild has been a Managing Director of HealthCare Ventures since 1992. Prior to joining HealthCare Ventures, he was the founding general partner of Advent International in Boston, after opening the London office of Advent U.K. He also held a similar position at Citicorp Venture Capital. Before his career in venture capital, Mr. Littlechild held marketing and financial management positions with Rank, Xerox and ICI.

Mr. Littlechild is a member of the board of fellows of the Council for Harvard Medicine.

Mr. Littlechild received his M.B.A. degree from Manchester Business School.

Robert Beall, PhD

Robert Beall has been with the Cystic Fibrosis Foundation (CF) for more than 26 years, serving as President and CEO for the past 11. Prior to joining the foundation, Dr. Beall was on the medical school faculty of Case Western Reserve University, and at the National Institutes of Health. Under his leadership, the CF Foundation has become one of the most respected voluntary health organizations in the country, recognized for its innovative approaches to bring new therapies to patients. The creation of its innovative Research Development Program in the 1980s has attracted leading institutions and scientists to the CF research effort. This collaborative network contributed to the identification of the CF gene in 1989. Since then, the focus has been on translating knowledge about the gene into the development of novel treatments. In 1998, the foundation launched its ground-breaking Therapeutics Development Program, a collaborative effort of industry, academics and the foundation to facilitate novel approaches to CF drug discovery and development

Edward J. Benz, Jr., MD

Edward J. Benz, Jr. M.D. is President and Chief Executive Officer of Dana-Farber Cancer Institute, CEO of Dana-Farber Partners Cancer Care, Principal Investigator and Director of the Dana-Farber/Harvard Cancer Center, Director of Dana Farber/Brigham and Women’s Cancer Center and a member of the Governing Board of Dana-Farber/Children's Hospital Cancer Center. He is the Richard and Susan Smith Professor of Medicine, Professor of Pediatrics, Professor of Pathology and Faculty Dean for Oncology at Harvard Medical School.

Benz is a graduate of Princeton University and Harvard Medical School. An internationally recognized hematologist, Dr. Benz received his training in internal medicine and hematology at Brigham and Women's Hospital, the National Institutes of Health, and the Yale University School of Medicine, and Immediately prior to assuming the presidency of Dana-Farber, he was the Physician in Chief and Chairman of the Department of Medicine at the Johns Hopkins University School of Medicine.

Having written several scholarly, peer reviewed articles, Benz is the associate editor of the New England Journal of Medicine for hematology and oncology. He has also served as associate editor of Blood, The American Journal of Hematology, and The American Journal of Medicine, as Faculty Head for hematology for the Faculty of 1000 online publication, and as Hematology Editor for Pocket Medicine, an online medical monograph series.

Dr. Benz's is a member of the Institute of Medicine of the National Academy of Sciences and the American Academy of Arts and Sciences. He was elected president of both the American Society of Hematology (1999-2000) and the American Society of Clinical Investigation (1991-1992). He currently serves as Past President of the Friends of the National Institute of Nursing Research, and has been elected President of the American Association of Cancer Institutes. He serves on the Board of External Advisors of the National Heart Lung and Blood Institute, and has served as Chair of the NIH Hematology Study Section and a member of the Advisory Council of the National Institute for Diabetes. He currently serves on the Rockefeller University Board of Trustees and Chairs the National Advisory Council of the Stanford University School of Medicine. Benz has also been selected to the National Cancer Policy Forum, and the advisory councils of the University of Pittsburgh School of Medicine, the Duke University Cancer Center, the Oregon Health Sciences University Cancer Center, the City of Hope Cancer Center, and the University of Florida Cancer Center.

Michael F. Collins, MD

Michael F. Collins, MD, a nationally respected education and health care policy advocate and leader of not for profit health care, was appointed Senior Vice President for Health Sciences at the University of Massachusetts and interim Chancellor of the University of Massachusetts Medical School in June of 2007.

Dr. Collins currently directs the University of Massachusetts system-wide health sciences efforts, charged with leading strategic initiatives to further the university's efforts in the Commonwealth's critical life sciences industry. As interim chancellor of the medical school, Dr. Collins, a Clinical Professor of Medicine, provides critical direction and leadership to the campus' continuing efforts to distinguish itself as a premier academic health sciences center of national distinction. Dr. Collins directs the campus' external outreach, focusing on expanding and enhancing relationships with the University Board, the UMass Memorial Health System, the community, the legislature and the philanthropic community. In addition, he provides guidance for institutional advancement and fundraising initiatives and administrative oversight and leadership for UMass Medical School enterprise operations, including Commonwealth Medicine and the Massachusetts Biologics Laboratories. Dr. Collins is also responsible for managing the institutional infrastructure, including oversight of finance and campus operations.

Dr. Collins was appointed chancellor of the University of Massachusetts Boston in 2005. In this role, he was charged with overseeing an institution renowned for its access to excellence and its diversity. The most diverse university in New England, the campus boasts a student population of 13,000, speaking over 90 languages. Chancellor Collins managed a university budget of $225 million and led an academic community of more than 800 full and part-time faculty. In the two years Chancellor Collins led UMass Boston, he initiated campus efforts to complete a strategic and master planning effort to increase enrollment, research support and philanthropic giving to garner local and national recognition for the UMass Boston programs; and, began much needed physical improvements to the campus.

Prior to joining UMass Boston, Dr. Collins served as president and chief executive officer of Caritas Christi Health Care System from 1994 to 2004. Under his leadership, Caritas Christi became the second-largest healthcare system in New England, generating more than $1.1 billion in annual revenues from six acute care hospitals, physician group practices, several extended care facilities and other healthcare entities, all located in eastern Massachusetts. From 1994 to 2001, Dr. Collins also served as president of St. Elizabeth's Medical Center in Brighton, a university academic medical center affiliated with Tufts University School of Medicine.

Chester Davis, Jr.

Bio available soon.

Peter Deckers, MD

Bio available soon.

Marijn Dekkers

Prior to the merger of Thermo Electron Corporation and Fisher Scientific International in November 2006, Dekkers was president and chief executive officer of Thermo Electron, a position he held since November 2002. During this time, Dekkers led a critical phase in the company's evolution, consolidating dozens of historically independent businesses into a single, fully integrated company focused entirely on the analytical instruments industry. He joined Thermo in July 2000 as chief operating officer.

Before Thermo Electron, Dekkers was employed for five years at Honeywell International (formerly AlliedSignal), where he held a number of executive positions. Dekkers began his career as a research scientist within General Electric's corporate R&D center in Schenectady New York. From 1985 to 1995, he held various operating positions within GE in both the United States and Europe.

A native of the Netherlands, Dekkers received both doctorate and master's degrees in chemical engineering from the University of Eindhoven and a bachelor's degree in chemistry from the University of Nijmegen.

Matthew D. Eyles

Matt is responsible for leading the Wyeth Public Policy department and the development of Wyeth public policy initiatives. The department works with public policy leaders inside and outside of government to shape the health policy agenda and related government decisions that will have an impact on the company and the research-based pharmaceutical industry. In addition, Matt plays a central role in managing the company’s involvement in industry trade associations, such as the Pharmaceutical Research and Manufacturers of America (PhRMA), Biotechnology Industry Organization (BIO), and the National Pharmaceutical Council (NPC). He is also a member of the Wyeth U.S. Management Team.

Matt joined Wyeth as Director, Federal Health Policy in 2001 from Eli Lilly and Company and has held several positions of increasing responsibility at Wyeth. Prior to his role at Lilly, Matt worked on Capitol Hill at the Congressional Budget Office (CBO) analyzing legislation reported by several committees of the U.S. House of Representatives and Senate.

Matt has undergraduate degrees from The George Washington University in Political Science and History and earned an M.S. in Public Policy from the University of Rochester (NY).

He lives in Trappe, Pennsylvania with his wife, Kirsten, and two children.

John Fallon, MD

John is responsible for ensuring the highest standards of medical care for our members. He is also responsible for helping expand health care strategies involving quality, effectiveness, and efficiency. He oversees the company’s medical policies, acts as the main liaison with the plan’s provider network, reviews upcoming legislation for medical impact, manages the company’s medical directors, acts as primary spokesperson for medical inquires and main medical contact with Blue Cross Blue Shield Association and its 39 plans.

John practiced Internal Medicine for over 20 years. Additionally, he was previously CEO for the entire clinical enterprise at the State University of New York’s Downstate Medical Center. His professional experience also includes the Partners Healthcare System, where he was Chairman of the physician network. He was also the founder and CEO of North Shore Health System, a physician-hospital organization involving more than 350 physicians and the North Shore Medical Center.

He serves on many boards; among them locally are the Neighborhood Health Plan and the New England Healthcare Institute, as well as, nationally the NCQA Medical Standards, and Temple University School of Medicine Board of Advisors.

John received a Bachelor’s degree from the College of the Holy Cross, his Master’s degree in Business Administration from the University of South Florida, his M.D. from Tufts Medical School in Boston, is Board Certified in Internal Medicine and is a Fellow of the American College of Physicians.

Jonathan Fleming

Jonathan Fleming is the Managing General Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science technology based investments, with offices in Boston and Connecticut.

Mr. Fleming has been in the investment business for over twenty years, starting and financing growth companies in the United States, Europe, and Israel. Prior to joining OBP in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming has also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage healthcare and biotechnology companies in Israel. Mr. Fleming holds a Master’s degree in Public Administration from Princeton University and a Bachelor of Arts degree from the University of California, Berkeley.

Mr. Fleming is a co-founder and Chairman of the Board of Memory Pharmaceuticals (NASDAQ: MEMY). He is also Chairman of the Board of BioProcessors Corporation and is a director of several private companies including Leerink Swann, a Boston based investment bank specializing in healthcare companies. Mr. Fleming is a Trustee of the Museum of Science in Boston and a Senior Lecturer at the MIT Sloan School of Business.

Joseph S. Gentile

Joseph Gentile is Vice President and General Manager for BD Biosciences, a division of BD (Becton, Dickinson & Co.). In this role, he develops strategies for the company’s market segments including stem cells, cell culture and cell environments, and forges strategic partnerships for the execution of these strategies. From 1998 to 2005, he was Director of Technology Strategy & Planning for BD Biosciences, where he transformed the business from a commodity lab plasticware supplier to a valued partner of researchers in life science and drug discovery. Prior to that, he served as Director of Technology Strategy & Planning for BD Corporate, which he joined in 1996.

From 1986 to 1996, Mr. Gentile held roles in program management and technology planning for Hewlett-Packard Co., where he designed and implemented strategy for a range of projects for the company’s Medical Products Group. Before joining HP, he served in engineering roles for AVCO Everett Research Lab, ELSCINT, Inc. And Advanced NMR Systems for fourteen years.

Mr. Gentile holds a B.S.E.E. from Northeastern University, and a M.S.E.E. and an M.B.A. from Boston University, and has completed continued education programs at Harvard University and the Massachusetts Institute of Technology. He is a Director of the New England Healthcare Institute, serves as an Advisory Board member for Tribiosys, Inc. and Vertify, Inc., and is a member of Mass BIO, Mass Medic and the Laboratory Products Association.

Donald J. Gudaitis

Donald J. Gudaitis became the first Chief Executive Officer of the American Cancer Society’s New England Division when the six New England states merged in 1997. For the previous decade, he served as the Executive Vice President of the Society’s Massachusetts Division. He currently leads or serves on numerous national-level American Cancer Society strategic teams.

Before coming to New England, Mr. Gudaitis served as the Executive Vice President for the American Cancer Society’s former Delaware Division for two years, and before that, as an Area Director for the former New Jersey Division. A graduate of Dickinson College with a major in psychology, he has completed the core M.B.A. program at Rutgers University. In 1993, Mr. Gudaitis was named one of the Ten Outstanding Young Leaders by the Boston Jaycees.

Razia Hashmi, MD

Dr. Hashmi is the Medical Director for the East Region of Anthem Blue Cross & Blue Shield, a subsidiary of Wellpoint, Inc. She provides clinical leadership for regional initiatives in medical management, quality, network management and cost of quality care programs for CT, NH, ME, NY, GA and VA. Dr. Hashmi joined Anthem in 2005 after nine years at Cigna Healthcare, where she served as Medical Director and Vice President for Coverage Policy. She was responsible for technology assessment, technology forecasting, clinical guidelines, benefit policies, claim policies and clinical support for new benefit development.

Dr. Hashmi practiced family medicine for 15 years in New York City. She completed her medical education at Jawaharlal Institute of Post-Graduate Medical Education and Research in Pondicherry, India and earned a Master Degree in Public Health at Columbia University. She completed a Post Doctoral Research Fellowship in Infectious Diseases at Johns Hopkins University Hospital. She is Board Certified in Family Practice with a Certificate of Added Qualification in Geriatrics.

Charles E. Hewett, PhD

Since early 2004, Charles E. (Chuck) Hewett has served as Vice President and Chief Operating Officer of The Jackson Laboratory, the world’s largest mammalian genetics research institution located in Bar Harbor, Maine. In that capacity, Dr. Hewett oversees the operations of the Laboratory and directs the Lab’s business which raises over two million mice per year for use in research laboratories around the world.

Dr. Hewett also serves as Chairman of Atlantic Energy Partners, a company that has successfully developed a $600 million project to provide a sub sea electrical connection between Long Island, New York and New Jersey. Dr. Hewett served as CEO of Atlantic Energy Partners from its founding in 1999 through April 2004 during which he also served as Vice President and Secretary to the Board of the Cianbro Companies, one of the East Coast’s largest heavy- infrastructure construction entities.

Dr. Hewett has developed and managed successful projects throughout the United States, Europe, and Asia including energy generation facilities, a pharmaceutical manufacturing company, and various forestry projects. In the mid 1990s, Dr. Hewett took a sabbatical from the private sector to serve for three years as the Chief Operating Officer of the Executive Branch of the State of Maine during Governor Angus King’s first term. In addition to directing State Government on behalf of the Governor, Dr. Hewett led the administrations’ successful downsizing and reorganization efforts.

Previously, Dr. Hewett led companies owned by Norwegian-based Hafslund Nycomed including the original development of a subsidiary, Nycomed Ireland, a pharmaceutical manufacturing enterprise. As President and CEO of another subsidiary, Dr. Hewett directed the Swift River Hafslund Company through successful restructuring and re-organization. Earlier in his career he served as Executive Director of the Maine Audubon Society and Director of Forest and Environmental Research at the Thayer School of Engineering, Dartmouth College. He also held posts with the U.S. Department of Interior in Alaska and Washington, D.C. Dr. Hewett has served on the boards of numerous organizations throughout Maine including the Maine Development Foundation which he chaired.

He currently serves on the Boards of Bangor Savings Bank, John Bapst Memorial High School, College of the Atlantic, the Maine Economic Research Institute, and the Kind Acts Foundation. Dr. Hewett is a graduate in political economy from Williams College and holds a Master of Forest Science degree and a PhD in Natural Resource Development, both from Yale University.

Vaughn M. Kailian

Vaughn M. Kailian previously served as vice chairperson of the Board of Directors of Millennium Pharmaceuticals, Inc.; and was head of the Millennium commercial organization, where he oversaw the integration of the COR Therapeutics commercial organization, expanded the cardiovascular sales effort and led the establishment of the Millennium commercial group which successfully launched VELCADE. Prior to joining Millennium, Mr. Kailian served from 1990 until 2002 as CEO, president and director of COR Therapeutics, Inc. He became the CEO of COR shortly after the company was founded, took the company public in 1991, raised almost $1 billion in public market capital, and lead the merger with Millennium in 2002.

Earlier in his career, Mr. Kailian held various international and U.S. general management, marketing and sales positions at Marion Merrell Dow, Inc. and its predecessor companies including president and general manager, Merrell Dow USA; and corporate vice president of Global Commercial Development, Marion Merrell Dow, Inc.

He is the Chairman of the Board of ViaCell, Inc.(NASDAQ:VIAC), Elixir Pharmaceuticals, Inc., Ikaria, Inc. He is also a director of NicOx, S.A. and Windhover Information, Inc. Mr. Kailian is currently a member of the board of BIO Ventures for Global Health and the Pharmaceutical Foundation Advisory Council at the University of Texas at Austin. Mr. Kailian joined MPM’s Boston office in May 2005. He earned his B.A. degree at Tufts University.

Kenneth Kaitin, PhD

Dr. Kaitin has served as the Director of the Tufts Center for the Study of Drug Development since 1998. He is also an Associate Professor of Medicine at Tufts University School of Medicine. Dr. Kaitin is an internationally recognized expert on the science of drug development. He publishes extensively on the factors that contribute to the slow pace and high cost of pharmaceutical R&D and the impact of regulatory and legislative initiatives to speed new drug development and review. He also testifies in Congress on drug development issues and is frequently quoted in the business and trade press on R&D trends in the research–based pharmaceutical industry.

Dr. Kaitin is a former president of the Drug Information Association and editor–in–chief of the Drug Information Journal. He received a B.S. from Cornell University and an M.S. and Ph.D. in pharmacology from the University of Rochester.

Paul Lammers, MD

Dr. Paul Lammers joined EMD Serono, Inc., formerly Serono, Inc., in July 2002 as Chief Medical Officer. In this role, he is responsible for the implementation in the US of all clinical development programs in support of both investigational and marketed products (Ph II-IV), regulatory affairs, and medical affairs. He started his pharmaceutical career in the Netherlands in 1989, after obtaining both a biology and medical degree, and moved to the US in 1992.

Before joining Serono, Inc., Dr. Lammers held several different management positions in clinical development, medical affairs, and regulatory affairs, at both medium and large pharmaceutical companies in New Jersey, and small private and public biotech companies in Texas. In these positions, he was involved in a wide variety of responsibilities, such as clinical research, clinical operations, medical services, medical information, regulatory affairs, and drug safety. He also worked as an independent consultant for start-up biotech companies.

Dr. Lammers is a member of the Drug Information Association, the American Academy of Pharmaceutical Physicians, and a member of the Board of the New England Healthcare Institute (NEHI).

Beverly Lorell, MD

Beverly H. Lorell, M.D. is the Senior Medical and Policy Advisor with King & Spalding's FDA/Healthcare Practice Group in Washington, D.C. Dr. Lorell specializes in the areas of clinical trial design of studies for drugs, devices and biologics; review of pre-market submissions; recalls; and assessment of matters involving a risk to health. She also specializes in the area of physician and industry relations and the development of independent scientific panels to advise health industries.

Dr. Lorell, who was previously Professor of Medicine at Harvard University, has over twenty-five years of experience as a practicing interventional cardiologist and heart failure specialist. She is an internationally recognized clinical and basic science investigator with extensive experience in multi-center clinical trials and preclinical proof-of-concept translational science. Prior to joining King & Spalding, Dr. Lorell served as Vice President and global Chief Medical and Technology Officer at Guidant Corporation. There her responsibilities included evaluating emerging technologies and attendant regulatory challenges, determining product development priorities, and influencing clinical research strategies. She participated in the firm's board for business development.

During her career at Harvard Medical School, she served the federal government in multiple roles including as a federally funded investigator of the National Institutes of Health and on the Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee.

Dr. Lorell has served in national leadership positions in professional societies. She was an Established Investigator of the American Heart Association (AHA). Additional honors include election as Fellow of the American College of Cardiology (FACC) and the American Heart Association (FAHA) and founding member of the Heart Failure Society of America. She served on the Executive Committees of both the Council on Clinical Cardiology and the Council on Basic Science of the AHA. Recent national leadership roles included the national Executive Committee of the Task Force on Clinical Competence of the ACC, AHA and American College of Physicians, a body which determines national standards for medical competency for novel cardiovascular technologies. She was also a member of the Consensus Conference Group on Professionalism and Ethics of the ACC and AHA. She continues to be an active invited lecturer at national professional meetings, as well as Harvard Law School and Harvard Medical School.

Dr. Lorell is a graduate of Stanford University, and she received her M.D. degree and her Residency in Internal Medicine from Stanford University Medical School. She received her advanced training as a Fellow in Cardiovascular Medicine at Harvard University. She is a Diplomate of the American Board of Internal Medicine, the Subspecialty Board of Cardiovascular Disease, and the Subspecialty Board of Interventional Cardiology. She is admitted to practice medicine in the states of California and Massachusetts. She is the author of over 160 medical science publications, 26 chapters and 2 books, including 8 recent publications in the area of health policy.

Martin D. Madaus, PhD, DVM

Martin D. Madaus is Chairman, President and Chief Executive Officer of Millipore Corporation. Millipore is a leading bioprocess and bioscience products and services company, organized into two divisions. The Bioprocess Division offers solutions that optimize development and manufacturing of biologics. The Bioscience Division provides high performance products and application insights that improve laboratory productivity. Dr. Madaus joined Millipore in January 2005 as President and Chief Executive Officer and became Chairman of the Board in March 2005.

Dr. Madaus came to Millipore from Roche Diagnostics Corporation where, as President and Chief Executive Officer, he led a $1.9 billion business. Prior to that, he was Vice President of Business Development for Roche Molecular Diagnostics. Dr. Madaus joined Roche in 1998 when he was general manager of Boehringer Mannheim Canada in Montreal, Quebec, through the acquisition of Boehringer Mannheim by Roche. From 1989 to 1998, Dr. Madaus worked at Boehringer Mannheim in senior management, sales and marketing, and product management roles both in Germany and in the United States.

John T. Mollen

Jack Mollen is Executive Vice President for Human Resources at EMC Corporation. With 2007 revenues of $13.2 billion and more than 37,000 employees, EMC is the world's leading developer and provider of information infrastructure technology and solutions that enable organizations of all sizes to transform the way they compete and create value from their information.

Jack Mollen leads EMC's global Human Resources practice to assure the availability of world-class talent to drive business success. His responsibilities include executive, leadership and employee development; compensation and benefits; staffing; and all of the people aspects of acquisition integration. Having joined EMC in September 1999, Jack reports to EMC Chairman, President and CEO Joseph M. Tucci. Jack has been an innovator in putting EMC at the forefront of influencing the health care marketplace to help control employee and company costs.

Jack is a director of the Human Resources Policy Association and is also an advisory board member for Working Mother Magazine, which promotes opportunity for women in business. Prior to EMC, Jack was with Citigroup Inc., where he was Vice President of Human Resources for Citigroup's 80,000-person Global Operations and Technology organization. He played a key employee-integration role following the 1998 merger of Citicorp and Travelers Group, Inc. Before joining Citigroup, Jack held a number of positions with Harris Corp., where as Vice President of Administration he was responsible for IS, Quality, Engineering Services, Human Resources, Mergers and Acquisitions, Facilities and Security for the company's 12,000-person Electronic Systems sector.

Jack holds a degree in Economics from St. John Fisher College in Rochester, New York and a Master's degree in Labor Relations from St. Francis College in Pennsylvania.

James Mongan, MD

James J. Mongan, M.D., is the president and chief executive officer of Partners HealthCare, a position he assumed on January 1, 2003. He chairs the Commission on a High Performance Health System and is also professor of health care policy and professor of social medicine at Harvard Medical School. From 1996-2002, Dr. Mongan served as president of Massachusetts General Hospital (MGH), the largest and oldest teaching affiliate of Harvard Medical School. Before his tenure at MGH, he served for 15 years as executive director of the Truman Medical Center in Kansas City and as dean of the University of Missouri-Kansas City School of Medicine. Prior to that, he spent 11 years in Washington, DC. He served as a staff member of the Senate Committee on Finance for seven years, working on Medicare and Medicaid legislation, and he served in the Carter administration as deputy assistant secretary for health and then at the White House as associate director of the domestic policy staff.

Dr. Mongan is a member of the Institute of Medicine of the National Academy of Sciences. He chairs The Commonwealth Fund Health Care Reform Program Advisory Committee. He has served on the board of trustees of the American Hospital Association and the Kaiser Family Foundation, and was a member of the Prospective Payment Assessment Commission established by Congress. A native of San Francisco, Dr. Mongan received his undergraduate education at the University of California, Berkeley and Stanford University, and his medical degree from Stanford University Medical School. He completed his internship at Kaiser Foundation Hospital in San Francisco and served two years in the public health service.

Thomas J. Moore, MD

Thomas J. Moore, MD is the Associate Provost for the Boston University Medical Campus and Director of the Office of Clinical Research at Boston University Medical Center. He is Professor of Medicine, Endocrinology and Nutrition at the BU School of Medicine, Co-director of the Master of Arts in Clinical Investigation program and the Medical School's liaison for the combined MD/MBA program.

Dr. Moore joined Boston University in 2001 and has since served in several leadership roles including Acting Provost for the BU Medical Campus in 2004-05 in addition to Acting Chairman of the Department of Medicine and Physician-in-Chief in 2005-06. Before joining the faculty of Boston University, he was a faculty member at Harvard Medical School and Physician at Brigham and Women's Hospital from 1977-2001. From 1995 till 2000, he was also Executive Medical Director with Merck and Co., Inc., directing Merck's medical and scientific affairs int eh northeast US.

Dr. Moore is an expert in the area of nutrition and blood pressure. He is a fellow of the Council for High Blood Pressure Research of the American Heart Association and was named a Specialist in Clinical Hypertension by the American Society of Hypertension. He has served as an investigator of a Specialized Center of Research (SCOR) grant in Hypertension, a program project grant on aging, and was the Chairman of the Steering Committee of the DASH trial, an NIH-funded multi-center trial of nutritional approaches to stop hypertension.

Joshua Ofman, MD

Joshua J. Ofman, MD, MSHS is the Vice President of Global Coverage & Reimbursement, Global Government Affairs and Vice President of Global Health Economics, Global Development. Dr. Ofman is Responsible for directing Amgen activities related to achieving coverage and reimbursement from National payers and oversight of evidence generation activities to demonstrate the economic value of Amgen products.

Dr. Ofman completed his undergraduate degree in the history and philosophy of science at University of California, Berkeley before completing his medical education at UC Irvine School of Medicine. He then completed his internship and residency in internal medicine at UCLA Medical Center. Following his residency, Dr. Ofman completed a two-year VA/UCLA/RAND fellowship in health services research, during which time he received his Masters of Science in Health Services (MSHS) degree from the UCLA School of Public Health. Dr. Ofman also completed a fellowship in gastroenterology at the UCLA integrated training program in digestive diseases. His research interests include health economics and technology assessment, program evaluation and health policy analysis, and he is widely published in these disciplines.

Dr. Ofman has served on several advisory boards for the American Gastroenterological Association, the American College of Physicians Clinical Efficacy Assessment Subcommittee, and is on the editorial board of the American Journal of Managed Care.

Prior to joining Amgen in 2003 as head of US Health Economics and Outcomes Research, Dr. Ofman was a member of the academic faculty in the Department of Medicine, UCLA School of Medicine, Cedars-Sinai Medical Center. Dr. Ofman also served as the Senior Vice President of Zynx Health Inc., a consulting company focused on evidence-based clinical information for quality improvement, and reimbursement and health economics strategy for life sciences companies.

Sandra Oliver

Sandra Oliver has more than 25 years experience in government affairs and sales management for two Fortune 500 companies with broad portfolios in Bio-Pharmaceuticals, Diagnostics and Chemicals. Sandy joined Bayer in June 2001 as Head of Public Policy and State Government Affairs for Bayer HealthCare LLC, and is responsible for developing and managing lobbying activities in 50 states on key public policy issues affecting Bayer’s Health Care companies. In 2006 Sandy was promoted to Vice President, Public Policy and State Government Affairs.

Prior to joining Bayer, Sandy directed state government affairs for Hoffmann-La Roche, Inc. Her career in state government affairs was preceded by more than 17 years in the sales and marketing organization of Syntex Pharmaceuticals, first as a sales representative and ultimately as a regional sales director overseeing a sales force of more than 100.

Additionally, Sandy represents Bayer on key committees and Boards of the Pharmaceutical Research and Manufacturer’s Association, Biotechnology Industry Organization (BIO) and the Connecticut Business and Industry Association (CBIA). She is on the Board of Directors of the American Legislative Exchange Council and the Greater New Haven Chamber of Commerce.

In 2002 Sandy was named Private Sector Member of the Year by the American Legislative Exchange Council. She has also been recognized by the YWCA of Bergen County, NJ Tribute to Women & Industry with the prestigious Twin Award. Sandy has a B.A. in Business Management from Eckerd College in St. Petersburg, Fla. She lives with her husband Bob in Pagosa Springs, CO.

Richard Pops

Mr. Pops became Chairman of Alkermes in April 2007. From 1991-2007, he served as Chief Executive Officer of Alkermes. Under his leadership, Alkermes grew from a privately held company with 25 employees to a publicly traded pharmaceutical company with more than 800 employees in multiple locations in the United States. Mr. Pops currently serves on the Board of Directors of: Alkermes, Inc.; Neurocrine Biosciences, Inc.; CombinatoRx, Inc.; Acceleron Pharma, Inc.; Sirtris Pharmaceuticals, Inc.; the Biotechnology Industry Organization (BIO); the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Harvard Medical School Board of Fellows.

Andrew J. Purcell

Mr. Purcell is responsible for Public Affairs, Business Development, Corporate Communications, Managed Markets, and Marketing Operations for the US affiliate of Novo Nordisk.

In the Public Affairs area Mr. Purcell has responsibility for Novo Nordisk’s “National Changing Diabetes Program,” a health policy initiative to stimulate the US healthcare system to evolve into one that is designed for better diabetes care and prevention.
He is the Chair of the ADA’s Board of Diabetes Industry Advisors. Mr. Purcell received his master’s degree in business administration from the University of Western Ontario, Canada, and his bachelor’s degree from the University of British Columbia, where he studied microbiology.

The Novo Nordisk vision is to be the world's leading diabetes care company and ultimately to defeat diabetes—and each employee takes this vision personally.

As a leading biotechnology healthcare company, Novo Nordisk has developed novel insulin and insulin analog formulations, as well as insulin injection systems, to improve the quality of care for people with diabetes. The company provides patient education programs, and offers tools for physicians, diabetes educators and other healthcare professionals to help get diabetes in better control. Beyond diabetes, Novo Nordisk holds a leading position in hemostasis management, growth hormone therapy, and hormone therapy for women. The company’s business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness and social responsibility to employees, customers and the communities in which it operates.

James Roosevelt, Jr.

Mr. Roosevelt joined Tufts Health Plan in 1999 as senior vice president and general counsel and held that position until June 2005, when he became president and chief executive officer. As the general counsel, he presided over the legal department and the company's compliance, privacy and government relations functions.

Before joining Tufts Health Plan, Mr. Roosevelt was the associate commissioner for Retirement Policy for the Social Security Administration in Washington, D.C. He has also served as chief legal counsel for the Massachusetts Democratic Party and is co-chair of the Rules and By-laws Committee of the Democratic National Committee. Mr. Roosevelt spent 10 years as partner at Choate, Hall and Stewart in Boston. He is past chairman of the board of trustees for the Massachusetts Hospital Association, past president of the American Health Lawyers Association and past chairman of the board of trustees for Mount Auburn Hospital. Currently, Mr. Roosevelt serves as chairman of the board of directors for Massachusetts Association of Health Plans, and as a member of the board of directors at America’s Health Insurance Plans, Emmanuel College and the Kenneth B. Schwartz Center. He is also co-chair of the board of directors for the Tufts Health Care Institute.

Mr. Roosevelt received his J.D. from Harvard Law School and his A.B. with honors in government from Harvard College. He has also completed the Advanced Management Program at Harvard Business School.

Steve H. Rusckowski

Before joining Philips Steve Rusckowski held numerous management positions with the healthcare division of Hewlett-Packard/Agilent Technologies. He was the General Manager of Agilent’s Healthcare Solutions Group when Philips acquired this business in 2001.

Mr. Rusckowski was previously the CEO of the Imaging Systems business group of Philips Healthcare. He was appointed Chief Executive Officer Philips Healthcare and member of the Group Management Committee on November 1, 2006. On April 1, 2007 he became a member of the Board of Management.

Mr. Rusckowski was born in 1957 in the United States and holds a Bachelor of Science in Mechanical Engineering from Worcester Polytechnic Institute and a degree in management science from the Mass Institute of Technology (MIT). He is married and has two children.

Una S. Ryan, PhD

Dr. Ryan has been Chief Executive Officer of AVANT since August 1996 and President, Chief Operating Officer and a director of AVANT since May 1996. Dr. Ryan joined AVANT as Vice President, Research and Chief Scientific Officer in May 1993. Dr. Ryan is also Research Professor of Medicine at Boston University School of Medicine and serves on its Board of Visitors. She is immediate past Chair of the Massachusetts Biotechnology Council, serves on its Board, as well as the Boards of the Biotechnology Industry Organization, the New England Healthcare Institute, IQuum, Inc., and AMRI, the Board of Associates of the Whitehead Institute, the Business Advisory Board of BIO Ventures for Global Health, the Scientific Advisory Board of Genocea, Inc. and the UMASS High Technology Executive Council. She is also a member of the Strategy & Policy Council of the MIT Center for Biomedical Innovation.

Dr. Ryan holds a Ph.D. in Cellular and Molecular Biology from Cambridge University and BS degrees in Zoology, Microbiology and Chemistry from Bristol University. In 2007, Dr. Ryan was honored as a recipient of the Albert Einstein Award for outstanding achievement in the life sciences. In 2006, Massachusetts Governor Romney appointed Dr. Ryan to the Robert H. Goddard Council on science, technology, engineering and mathematics education. In 2002 Her Majesty Queen Elizabeth II awarded Dr. Ryan the Order of the British Empire (OBE) for her services to the research, development and promotion of biotechnology.

Eve Slater, MD

Dr. Eve Slater, a distinguished leader in biomedical science and healthcare policy, joined Pfizer as Senior Vice President, Worldwide Policy on May 1. Eve is a member of the Worldwide Public Affairs and Policy Leadership Team and reports to Rich Bagger.

Eve’s career in medicine, science and public policy has spanned academics, business and government. She was most recently Assistant Secretary of Health for the U.S. Department of Health and Human Services. Prior to joining HHS, she spent 19 years with Merck in a number of critical scientific, strategy and public policy positions. In 1983, she came to Merck Research Laboratories as senior director of biochemical endocrinology, and in 1988, she was promoted to vice president, regulatory affairs. She advanced to VP of clinical and regulatory development for Merck Research Laboratories in 1990, and SVP in 1994. In 2001, she was named as SVP of External Policy for Merck Research Laboratories, and VP of Merck Corporate Public Affairs. An expert on HIV treatment research, she served as a member of the U.S. Keystone National Policy Dialogue on HIV, as well as the NIH Office of AIDS Research Advisory Council.

Eve was appointed by the President in 2001 as Assistant Secretary of Health, the first woman to hold this position. In this role, she served HHS Secretary Tommy Thompson as chief health policy advisor, with special emphasis on e-health and innovation, biosecurity, clinical trial protocols, women’s health, eldercare and HIV/AIDS. Since leaving HHS, she has been a director and advisor to a number of biotechnology companies.

Eve received her B.A. from Vassar and her M.D. from Columbia. She was the first woman named as Chief Resident at Massachusetts General Hospital, where she later led the Hypertension Unit. She also served as Assistant Professor of Medicine at Harvard Medical School. She continues to serve patients as an Associate Attending Physician at NY Presbyterian Hospital and the medical profession as an Associate Professor of Medicine at Columbia.

David F. Torchiana, MD

Dr. Torchiana graduated from Yale College in 1976. He spent the following year as a Churchill Scholar at Cambridge University, Cambridge UK, doing research in the Physiology Laboratory. He subsequently graduated from Harvard Medical School in 1981.

 Dr. Torchiana completed residencies in general surgery and cardiothoracic surgery at the MGH before joining the Department of Surgery there in 1989. He became Chief of Cardiac Surgery in 1998 and is an Associate Professor of Surgery at Harvard Medical School. In January 2003, he assumed the role of Chairman and Chief Executive Officer of the Massachusetts General Physicians Organization.

The MGPO, associated with the Massachusetts General Hospital, is a member of the Partners Health Care System and a teaching affiliate of the Harvard Medical School. The organization is a non-profit, tax-exempt corporation and the largest physician group practice in New England, representing more than 1,500 physicians.

Josef H. von Rickenbach

As Chairman and Chief Executive Officer of PAREXEL, Josef von Rickenbach has created one of the world's largest pharmaceutical outsourcing companies. In Fiscal 2001, the company had annual revenues in excess of $387 million, operations in more than 43 countries, and approximately 4,700 employees worldwide. Since its inception in 1983, PAREXEL has grown to provide a broad range of expertise-based product development and marketing outsourcing services to the international pharmaceutical, biotechnology, and medical device industries.

Under Mr. von Rickenbach’s leadership, PAREXEL has expanded geographically and operationally through a number of acquisitions; conceived and established a highly complex, multi-disciplinary, systems-oriented and global approach to clinical research, biostatistics and data management operations.
Prior to founding PAREXEL, Mr. von Rickenbach was employed by ENSECO (formerly ERCO), as the Manager of European Operations. He began his career at Schering-Plough, Inc. in Lucerne, Switzerland.

Mr. von Rickenbach presents regularly at North American and European investor and industry conferences, and pharmaceutical and other professional industry meetings. He was awarded the Ernst & Young 1997 New England Region Entrepreneur of the Year.

Mr. von Rickenbach holds a Bachelor of Business Administration from the Lucerne College of Industrial Economics and Administration in Switzerland and received his Masters of Business Administration from the Harvard University Graduate School of Business Administration.